Sign In
Buy ZYME
$24.35
+0.240 (+1.00%)
At Close: Jun 03, 2026
Here's Why Zymeworks Inc. (ZYME) is Poised for a Turnaround After Losing 24.1% in 4 Weeks
12:17pm, Monday, 11'th Oct 2021
Zymeworks Inc. (ZYME) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in rev
Zymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial
11:43am, Thursday, 16'th Sep 2021
At the European Society of Medical Oncology Congress 2021 (ESMO21), Zymeworks Inc (NYSE: ZYME) presented encouraging early data on its HER2‑targeted bispecific antibody. Twenty-eight patients were d
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that new clinical data
VANCOUVER, British Columbia--(BUSINESS WIRE)--This press release announces the availability of an abstract that Zymeworks is presenting at the upcoming ESMO Congress
New Strong Sell Stocks for August 10th
10:53am, Tuesday, 10'th Aug 2021
THS, ZYME, NTRA, LAWS, and INSW have been added to the Zacks Rank #5 (Strong Sell) List on August 10, 2021
Zymeworks Inc. (ZYME) Reports Q2 Loss, Lags Revenue Estimates
09:20pm, Wednesday, 04'th Aug 2021
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -23.58% and -75.61%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
5 Mid-Cap Healthcare Stocks You'll Want on Your Radar for the 2nd Half of 2021
07:01am, Friday, 23'rd Jul 2021
These biotech stocks could have great long-term potential.
Zymeworks: Drop Due To Low Differentiation Against Competition
05:23am, Monday, 05'th Jul 2021
Zymeworks: Drop Due To Low Differentiation Against Competition
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
10:10pm, Wednesday, 05'th May 2021
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 14.71% and -90.65%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
BlackBerry, Lam Research, Shopify, Square, Zoom and More Wednesday Afternoon Analyst Calls
11:50am, Wednesday, 31'st Mar 2021
With the trading day about halfway over, the broad markets largely were pushing higher, except for the Dow Jones industrial average.
Is It Too Late to Buy Zymeworks Stock?
06:55am, Monday, 22'nd Mar 2021
The clinical-stage antibody treatment developer has a fair way to go before it gets a product to market -- but it's not going it alone.
Zymeworks Announces Five Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
05:27pm, Wednesday, 10'th Mar 2021
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the acceptance of five
Zymeworks: Moving Up On My Watch List
02:25am, Friday, 26'th Feb 2021
Zymeworks: Moving Up On My Watch List
Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
01:41pm, Monday, 22'nd Feb 2021
Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks Expands Commercial Team and Creates New R&D Role
04:30pm, Tuesday, 09'th Feb 2021
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that James Priour, for
